Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...

Have you been paying attention to shares of Gilead Sciences (GILD)? Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the ...

GILD opened at $116.04 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

NASDAQ GILD opened at $109.95 on Friday. The business has a 50 day simple moving average of $95.41 and a 200 day simple moving average of $88.63. Gilead Sciences has a 52-week low of $62.07 and a ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, and downgraded Merck (NYSE:MRK), citing the cancer drugmaker’s ...